In accord with ASX requirements, Imagion Biosystems’ 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update includes Appendix 4C and commentary on the Company’s progress toward the first in-human clinical studies of its proprietary MagSense® technology.
View Imagion Biosystems December 2017 Quarterly Update.
The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials
September 4, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required